The prevailing Th2 profile in advanced CTCL underscores the significance of understanding IL-4/IL-13 expression dynamics from the early stages of disease, as a shift from Th1 to Th2 may explain CTCL progression. The gene discussed is IL13; the disease is primary cutaneous T-cell non-Hodgkin lymphoma.